EBITDA margin společnosti Beam Therapeutics
Jaká je hodnota metriky EBITDA margin společnosti Beam Therapeutics?
Hodnota metriky EBITDA margin společnosti Beam Therapeutics Inc. je -35.52%
Jaká je definice metriky EBITDA margin?
EBITDA margin is a profitability ratio that measures how much EBITDA the company generates as a percentage of revenue.
ttm (trailing twelve months)
EBITDA margin measures how much of EBITDA is generated as a percentage of sales. It measures the company’s operating profit as a percentage of its revenue and is calculated as EBITDA (earnings before interest, taxes, depreciation, and amortization) divided by total revenue.
EBITDA margin also helps with judging the effectiveness of cost-cutting processes at the company. The higher the company’s EBITDA margin, the lower operating expenses are in respect to revenue. As a result, a higher EBITDA margin is considered more favorable. Smaller companies can have higher EBITDA margins since they are able to operate more efficiently and maximize their profitability.
EBITDA excludes interest on debt, taxes, and capital expenditures, the margin does not provide a perfectly clear estimate of the business’s cash flow generation. Furthermore, EBITDA margin is not recognized as a GAAP (generally accepted accounting principles) metric.
EBITDA margin společností v sektoru Health Care sektor na NASDAQ ve srovnání se společností Beam Therapeutics
Čemu se věnuje společnost Beam Therapeutics?
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia. It also develops therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1a; and therapies for ocular and central nervous system disorders. The company has a strategic alliance with Boston Children's Hospital; a research and clinical collaboration agreement with Magenta Therapeutics, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration with Apellis Pharmaceuticals, Inc. to apply base editing technology for discovering new treatments for complement-driven diseases. Beam Therapeutics Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Firmy s metrikou ebitda margin podobnou společnosti Beam Therapeutics
- Hodnota metriky EBITDA margin společnosti Tellurian Inc je -35.70%
- Hodnota metriky EBITDA margin společnosti Quanterix Corp je -35.66%
- Hodnota metriky EBITDA margin společnosti Vicinity Motor je -35.63%
- Hodnota metriky EBITDA margin společnosti KNT je -35.61%
- Hodnota metriky EBITDA margin společnosti Medical Properties Trust Inc je -35.61%
- Hodnota metriky EBITDA margin společnosti Texmaco Infrastructure & je -35.58%
- Hodnota metriky EBITDA margin společnosti Beam Therapeutics je -35.52%
- Hodnota metriky EBITDA margin společnosti Oatly AB je -35.52%
- Hodnota metriky EBITDA margin společnosti Green International je -35.51%
- Hodnota metriky EBITDA margin společnosti Althea je -35.46%
- Hodnota metriky EBITDA margin společnosti Ambarella Inc je -35.46%
- Hodnota metriky EBITDA margin společnosti The Ravalgaon Sugar Farm je -35.39%
- Hodnota metriky EBITDA margin společnosti Oryzon Genomics S.A je -35.35%